National Data Bank for Rheumatic Disease Registry Study of Safety in Patients With Rheumatoid Arthritis Treated With Cimzia® or Disease-modifying Antirheumatic Drugs (DMARDs)
Status
Completed
Conditions
Rheumatoid Arthritis
Details and patient eligibility
About
Observational registry to assess the longer-term risk of serious infections and malignancies reported with TNFα-blocker therapy, as well as the longer-term risk of cardiovascular and thromboembolic events in adult Rheumatoid Arthritis (RA) patients treated with Cimzia® as compared to non-biologic DMARD-treated controls.
Enrollment
12,500 patients
Sex
All
Volunteers
No Healthy Volunteers
Inclusion and exclusion criteria
Inclusion Criteria:
- RA and started treatment with certolizumab pegol (Cimzia®; CZP) or non-biologic DMARD within the last 6 months
Trial design
12,500 participants in 2 patient groups
Certolizumab pegol (CZP)
Description:
Patients with RA receiving treatment with certolizumab pegol (CZP; Cimzia®)
Non-biologic DMARD
Description:
Subjects with RA receiving treatment with non-biologic DMARD
Trial contacts and locations
0
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal
© Copyright 2026 Veeva Systems